0001104659-24-065645.txt : 20240528 0001104659-24-065645.hdr.sgml : 20240528 20240528170138 ACCESSION NUMBER: 0001104659-24-065645 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240523 FILED AS OF DATE: 20240528 DATE AS OF CHANGE: 20240528 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nayak Sanjay CENTRAL INDEX KEY: 0002012715 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36554 FILM NUMBER: 24992869 MAIL ADDRESS: STREET 1: C/O OCULAR THERAPEUTIX, INC. STREET 2: 24 CROSBY DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OCULAR THERAPEUTIX, INC CENTRAL INDEX KEY: 0001393434 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 15 CROSBY DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: 781-357-4000 MAIL ADDRESS: STREET 1: 15 CROSBY DRIVE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: I-THERAPEUTIX INC DATE OF NAME CHANGE: 20070315 4 1 tm2415610-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-05-23 0 0001393434 OCULAR THERAPEUTIX, INC OCUL 0002012715 Nayak Sanjay C/O OCULAR THERAPEUTIX, INC. 15 CROSBY DRIVE BEDFORD MA 01730 0 1 0 0 Chief Strategy Officer 1 Common Stock 2024-05-23 4 S 0 2274 5.84 D 178026 D Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on May 22, 2024. The sales do not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.77 to $5.92, inclusive. The reporting person undertakes to provide to the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. /s/ Donald Notman, Attorney-in-Fact for Sanjay Nayak 2024-05-28